More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes ...
More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes Project.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
Concurrent DNA and RNA sequencing revealed 15.3% more patients with actionable variants than DNA sequencing alone.
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...
CODA, the first ever 3D genome profiling technique, was able to make a 3D print of pre-cancerous cells found in a human ...
More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes ...
Researchers analyzed whole-genome sequencing data from 76,805 patients to identify variants in 4 genes that are associated ...
With whole-genome sequencing and computational tools, the researchers identified genetic mutations and structural variations ...
More than half of midlands-based cancer patients whose genomes were successfully sequenced through the 100,000 Genomes Project, received clinical recommendations according to a new study published in ...
Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...
In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...